{"protocolSection": {"identificationModule": {"nctId": "NCT01841697", "orgStudyIdInfo": {"id": "3102-026"}, "secondaryIdInfos": [{"id": "2013-000059-42", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)", "officialTitle": "A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-06-13", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2014-11-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-11-17", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-04-24", "studyFirstSubmitQcDate": "2013-04-24", "studyFirstPostDateStruct": {"date": "2013-04-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-23", "resultsFirstSubmitQcDate": "2015-10-23", "resultsFirstPostDateStruct": {"date": "2015-11-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-08-09", "lastUpdatePostDateStruct": {"date": "2018-09-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This is a non-inferiority study comparing omarigliptin with sitagliptin in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on metformin therapy. The primary hypothesis is that after 24 weeks, the mean change from baseline in hemoglobin A1c (A1C) in participants treated with omarigliptin is non-inferior to that in participants treated with sitagliptin. There will be a 2-week run-in period with placebo + metformin prior to the double-blind treatment period."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"], "keywords": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Glucose Metabolism Disorders", "Metabolic Diseases", "Endocrine System Diseases", "Glimepiride", "Metformin", "Hypoglycemic Agents", "Physiological Effects of Drugs", "Pharmacologic Actions"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 642, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Omarigliptin 25 mg once weekly", "type": "EXPERIMENTAL", "description": "Participants receive omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.", "interventionNames": ["Drug: Omarigliptin", "Drug: Placebo to Sitagliptin", "Drug: Open-label Metformin", "Drug: Open-label Glimepiride"]}, {"label": "Sitagliptin 100 mg once daily", "type": "ACTIVE_COMPARATOR", "description": "Participants receive sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.", "interventionNames": ["Drug: Sitagliptin", "Drug: Placebo to omarigliptin", "Drug: Open-label Metformin", "Drug: Open-label Glimepiride"]}], "interventions": [{"type": "DRUG", "name": "Omarigliptin", "description": "Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks", "armGroupLabels": ["Omarigliptin 25 mg once weekly"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "Sitagliptin 100 mg oral tablet once a day for 24 weeks", "armGroupLabels": ["Sitagliptin 100 mg once daily"]}, {"type": "DRUG", "name": "Placebo to omarigliptin", "description": "Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks", "armGroupLabels": ["Sitagliptin 100 mg once daily"]}, {"type": "DRUG", "name": "Placebo to Sitagliptin", "description": "Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks", "armGroupLabels": ["Omarigliptin 25 mg once weekly"]}, {"type": "DRUG", "name": "Open-label Metformin", "description": "Metformin oral tablet(s) - total daily dose of \u22651500 mg, once or twice a day", "armGroupLabels": ["Omarigliptin 25 mg once weekly", "Sitagliptin 100 mg once daily"], "otherNames": ["Fortamet\u00ae", "Glucophage\u00ae", "Glucophage\u00ae XR", "Glumetza\u00ae", "Riomet\u00ae"]}, {"type": "DRUG", "name": "Open-label Glimepiride", "description": "Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy", "armGroupLabels": ["Omarigliptin 25 mg once weekly", "Sitagliptin 100 mg once daily"], "otherNames": ["Amaryl\u00ae", "Glimy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 24", "description": "A1C is a measure of the percentage of glycated hemoglobin in the blood. Participant whole blood samples were collected at baseline and Week 24 to determine the least squares mean A1C change from baseline.", "timeFrame": "Baseline and Week 24"}, {"measure": "Percentage of Participants Who Experienced at Least One Adverse Event", "description": "An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after initiation of glycemic rescue therapy.", "timeFrame": "Up to 27 weeks (including 3-week follow-up)"}, {"measure": "Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event", "description": "An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after initiation of glycemic rescue therapy.", "timeFrame": "Up to 24 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in FPG at Week 24", "description": "Participant whole blood samples were collected after an overnight fast at baseline and Week 24 to determine the least squares mean change from baseline in participant FPG.", "timeFrame": "Baseline and Week 24"}, {"measure": "Percentage of Participants Achieving an A1C Goal <7.0% After 24 Weeks of Treatment", "description": "Participant whole blood samples were collected at Week 24 to determine the number of participants achieving A1C \\<7.0% at Week 24.", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Achieving an A1C Goal <6.5% After 24 Weeks of Treatment", "description": "Participant whole blood samples were collected at Week 24 to determine the percentage of participants achieving A1C \\<6.5% at Week 24.", "timeFrame": "Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus\n* Currently on a stable dose of metformin monotherapy (\u22651500 mg per day) for at least 12 weeks prior to study participation\n* Male, or female who is not of reproductive potential or if of reproductive potential agrees to abstain from heterosexual activity or use (or have their partner use) acceptable contraception to prevent pregnancy during the study and for 21 days after the last dose of study drug\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus or a history of ketoacidosis\n* Has been treated with any antihyperglycemic agent (AHA) other than the protocol-required metformin within 12 weeks prior to study participation or with omarigliptin at any time prior to signing informed consent\n* History of hypersensitivity to a dipeptidyl peptidase IV (DPP-4) inhibitor\n* Is currently participating in, or has participated in, a trial in which the participant received an investigational compound or used an investigational device within the prior 12 weeks of signing the informed consent or is not willing to refrain from participating in any other trial\n* History of intolerance, hypersensitivity, or any other contraindication to metformin or sitagliptin\n* Is on a weight loss program and is not in the maintenance phase or has been on a weight loss medication in the past 6 months or has undergone bariatric surgery within 12 months prior to study participation\n* Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study\n* Is on or likely to require treatment \u226514 consecutive days or repeated courses of corticosteroids (inhaled, nasal and topical corticosteroids are permitted)\n* Currently being treated for hyperthyroidism or is on thyroid hormone replacement therapy and has not been on a stable dose for at least 6 weeks\n* Is expecting to undergo hormonal therapy in preparation to donate eggs during the period of the trial, including 21 days after the last dose of trial medication\n* History of active liver disease (other than non-alcoholic steatosis) including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gall bladder disease\n* Human immunodeficiency virus (HIV)\n* New or worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months, or myocardial infarction, unstable angina, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, stroke, or transient ischemic attacks in the past 3 months\n* Poorly controlled hypertension\n* History of malignancy \u22645 years prior to study participation, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n* Hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n* Positive urine pregnancy test\n* Pregnant or breastfeeding, or is expecting to conceive during the study including 21 days following the last dose of blinded study drug\n* User of recreational or illicit drugs or has had a recent history of drug abuse\n* Routinely consumes \\>2 alcoholic drinks per day or \\>14 alcoholic drinks per week, or engages in binge drinking\n* Has donated blood products or has had phlebotomy of \\>300 mL within 8 weeks of study participation, or intends to donate blood products within the projected duration of the trial or has received, or is anticipated to receive, blood products within 12 weeks of study participation or within the projected duration of the trial", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "28093853", "type": "RESULT", "citation": "Goldenberg R, Gantz I, Andryuk PJ, O'Neill EA, Kaufman KD, Lai E, Wang YN, Suryawanshi S, Engel SS. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2017 Mar;19(3):394-400. doi: 10.1111/dom.12832. Epub 2017 Jan 17."}], "availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/study.html?id=3102-026&kw=3102-026&tab=access"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Omarigliptin 25 mg Once Weekly", "description": "Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}, {"id": "FG001", "title": "Sitagliptin 100 mg Once Daily", "description": "Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "322"}, {"groupId": "FG001", "numSubjects": "320"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "302"}, {"groupId": "FG001", "numSubjects": "302"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "18"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "16"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Omarigliptin 25 mg Once Weekly", "description": "Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}, {"id": "BG001", "title": "Sitagliptin 100 mg Once Daily", "description": "Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "322"}, {"groupId": "BG001", "value": "320"}, {"groupId": "BG002", "value": "642"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.0", "spread": "9.8"}, {"groupId": "BG001", "value": "57.6", "spread": "9.8"}, {"groupId": "BG002", "value": "57.3", "spread": "9.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "171"}, {"groupId": "BG001", "value": "145"}, {"groupId": "BG002", "value": "316"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "151"}, {"groupId": "BG001", "value": "175"}, {"groupId": "BG002", "value": "326"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.52", "spread": "0.77"}, {"groupId": "BG001", "value": "7.49", "spread": "0.74"}, {"groupId": "BG002", "value": "7.50", "spread": "0.76"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "160.1", "spread": "35.7"}, {"groupId": "BG001", "value": "153.9", "spread": "32.8"}, {"groupId": "BG002", "value": "157.0", "spread": "34.4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C at Week 24", "description": "A1C is a measure of the percentage of glycated hemoglobin in the blood. Participant whole blood samples were collected at baseline and Week 24 to determine the least squares mean A1C change from baseline.", "populationDescription": "Full analysis set population consists of all randomized participants who received at least one dose of study treatment and have a baseline measurement or a post-randomization measurement for the analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg Once Weekly", "description": "Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}, {"id": "OG001", "title": "Sitagliptin 100 mg Once Daily", "description": "Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "322"}, {"groupId": "OG001", "value": "320"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "lowerLimit": "-0.55", "upperLimit": "-0.38"}, {"groupId": "OG001", "value": "-0.43", "lowerLimit": "-0.51", "upperLimit": "-0.35"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Constrained longitudinal data analysis", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If the upper bound of the two-sided 95% confidence interval for the mean difference between omarigilptin and sitagliptin is less than the non-inferiority margin, \u03b4 =0.3%, then omarigliptin will be declared non-inferior to sitagliptin in terms of A1C reduction at Week 24.", "paramType": "Difference in least squares mean", "paramValue": "-0.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.15", "ciUpperLimit": "0.08", "estimateComment": "Difference is omarigliptin minus sitagliptin."}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced at Least One Adverse Event", "description": "An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after initiation of glycemic rescue therapy.", "populationDescription": "All participants as treated population consists of all randomized participants who received at least one dose of trial treatment. Participants are included in the treatment group corresponding to the trial treatment they actually received.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 27 weeks (including 3-week follow-up)", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg Once Weekly", "description": "Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}, {"id": "OG001", "title": "Sitagliptin 100 mg Once Daily", "description": "Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "322"}, {"groupId": "OG001", "value": "320"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36.3"}, {"groupId": "OG001", "value": "40.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percent", "paramValue": "-4.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.8", "ciUpperLimit": "3.2", "estimateComment": "Difference is omarigliptin minus sitagliptin."}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event", "description": "An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after initiation of glycemic rescue therapy.", "populationDescription": "All participants as treated population consists of all randomized participants who received at least one dose of trial treatment. Participants are included in the treatment group corresponding to the trial treatment they actually received.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 24 weeks", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg Once Weekly", "description": "Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}, {"id": "OG001", "title": "Sitagliptin 100 mg Once Daily", "description": "Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "322"}, {"groupId": "OG001", "value": "320"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "2.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percent", "paramValue": "-1.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.6", "ciUpperLimit": "0.8", "estimateComment": "Difference is omarigliptin minus sitagliptin."}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG at Week 24", "description": "Participant whole blood samples were collected after an overnight fast at baseline and Week 24 to determine the least squares mean change from baseline in participant FPG.", "populationDescription": "Full analysis set population consists of all randomized participants who received at least one dose of study treatment and have a baseline measurement or a post-randomization measurement for the analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg Once Weekly", "description": "Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}, {"id": "OG001", "title": "Sitagliptin 100 mg Once Daily", "description": "Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "322"}, {"groupId": "OG001", "value": "320"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.7", "lowerLimit": "-17.3", "upperLimit": "-10.1"}, {"groupId": "OG001", "value": "-9.5", "lowerLimit": "-13.2", "upperLimit": "-5.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.089", "statisticalMethod": "Constrained logitudinal data analysis", "statisticalComment": "Terms for treatment, time, and the interaction of time by treatment, with the constraint that the mean baseline is the same for all treatment groups.", "paramType": "Difference in least squares mean", "paramValue": "-4.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.0", "ciUpperLimit": "0.6", "estimateComment": "Difference is omarigliptin minus sitagliptin."}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving an A1C Goal <7.0% After 24 Weeks of Treatment", "description": "Participant whole blood samples were collected at Week 24 to determine the number of participants achieving A1C \\<7.0% at Week 24.", "populationDescription": "Full analysis set population consists of all randomized participants who received at least one dose of study treatment and have a baseline measurement or a post-randomization measurement for the analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg Once Weekly", "description": "Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}, {"id": "OG001", "title": "Sitagliptin 100 mg Once Daily", "description": "Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "322"}, {"groupId": "OG001", "value": "320"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50.9", "lowerLimit": "48.8", "upperLimit": "59.9"}, {"groupId": "OG001", "value": "49.1", "lowerLimit": "46.8", "upperLimit": "57.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Proportion (rate) for each group was estimated using standard multiple imputation techniques. Between-group difference in proportion is omarigliptin minus sitagliptin.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.619", "statisticalMethod": "Miettinen & Nurminen method", "paramType": "Between-group rate difference", "paramValue": "2.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.9", "ciUpperLimit": "9.9"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving an A1C Goal <6.5% After 24 Weeks of Treatment", "description": "Participant whole blood samples were collected at Week 24 to determine the percentage of participants achieving A1C \\<6.5% at Week 24.", "populationDescription": "Full analysis set population consists of all randomized participants who received at least one dose of study treatment and have a baseline measurement or a post-randomization measurement for the analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg Once Weekly", "description": "Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}, {"id": "OG001", "title": "Sitagliptin 100 mg Once Daily", "description": "Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "322"}, {"groupId": "OG001", "value": "320"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.0", "lowerLimit": "24.0", "upperLimit": "34.1"}, {"groupId": "OG001", "value": "22.8", "lowerLimit": "19.9", "upperLimit": "29.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Proportion (rate) for each group was estimated using standard multiple imputation techniques. Between-group difference in proportion is omarigliptin minus sitagliptin.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.212", "statisticalMethod": "Miettinen & Nurminen method", "paramType": "Between-group rate difference", "paramValue": "4.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.5", "ciUpperLimit": "11.4"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 27 weeks (including 3-week follow-up)", "description": "All participants as treated population defined as all randomized participants who received at least 1 dose of study drug. Participants are included in the treatment group corresponding to the trial treatment they actually received. Serious and non-serious AEs, respectively, include and exclude data after the initiation of glycemic rescue therapy.", "eventGroups": [{"id": "EG000", "title": "Omarigliptin 25 mg Once Weekly", "description": "Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy.", "seriousNumAffected": 11, "seriousNumAtRisk": 322, "otherNumAffected": 0, "otherNumAtRisk": 322}, {"id": "EG001", "title": "Sitagliptin 100 mg Once Daily", "description": "Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose \u22651500 mg) throughout the study. Participants may have received glimepiride (total daily dose of 1-6 mg) as rescue therapy.", "seriousNumAffected": 9, "seriousNumAtRisk": 320, "otherNumAffected": 0, "otherNumAtRisk": 320}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Arrhythmia supraventricular", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Hypothyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Non-small cell lung cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Sebaceous adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Cerebrovascular disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Diabetic neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}, {"term": "Dematitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Psoriasis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 320}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 322}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 320}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Canada", "Croatia", "Estonia", "Georgia", "Hungary", "Israel", "Malaysia", "Philippines", "Poland", "Romania", "South Africa", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000057619", "term": "Glimepiride"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Game", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}